Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pulmonary arterial hypertension: therapeutic algorithm.

Nazzareno Galiè1, Angelo Branzi

  • 1Institute of Cardiology, University of Bologna, Bologna, Italy. n.galie@bo.nettuno.it

Italian Heart Journal : Official Journal of the Italian Federation of Cardiology
|November 8, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pulmonary artery dilation in pulmonary arterial hypertension: haemodynamic determinants and association with sudden death.

European journal of internal medicine·2026
Same author

Modern and multidisciplinary care in polycythemia vera.

Annals of hematology·2026
Same author

2025 expert consensus on the use of parenteral prostanoids in incident and prevalent PAH patients: The Italian perspective.

Vascular pharmacology·2026
Same author

Predictors of long-term structural valve deterioration and failure after transcatheter aortic valve implantation.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2026
Same author

Evaluating oral selexipag in pulmonary arterial hypertension: Insights on survival, safety, and dosing patterns from the complete observation period of GRIPHON and its open-label extension.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2025
Same author

Influence of age in the assessment of therapeutic response in patients with pulmonary arterial hypertension.

ERJ open research·2025
Same journal

Effective method to control catastrophic hemorrhage during redo sternotomy.

Italian heart journal : official journal of the Italian Federation of Cardiology·2006
Same journal

Double aneurysm of the left ventricular wall following cardiac perforation after aortic valvuloplasty.

Italian heart journal : official journal of the Italian Federation of Cardiology·2006
Same journal

Surgical treatment of an aneurysm originating from a Kommerell's diverticulum in the right-sided aortic arch with retroesophageal component.

Italian heart journal : official journal of the Italian Federation of Cardiology·2006
Same journal

A clinical approach for cardiovascular monitoring of HIV-infected patients. Results from an observational cohort study.

Italian heart journal : official journal of the Italian Federation of Cardiology·2006
Same journal

Ectasia of the ascending aorta at the time of aortic valve surgery: replace or relax?

Italian heart journal : official journal of the Italian Federation of Cardiology·2006
Same journal

Evidence for a "gender paradox" in diabetic patients undergoing percutaneous coronary intervention: adverse preprocedural risk but favorable long-term clinical outcome in women.

Italian heart journal : official journal of the Italian Federation of Cardiology·2006
See all related articles

Evidence-based guidelines now inform pulmonary arterial hypertension (PAH) treatment, focusing on NYHA class III/IV patients. Treatment selection depends on patient response and specific PAH type, with advanced options for refractory cases.

Area of Science:

  • Cardiology
  • Pulmonology
  • Pharmacology

Background:

  • Pulmonary arterial hypertension (PAH) management has evolved from clinical judgment to evidence-based strategies.
  • Recent controlled clinical trials provide robust data for therapeutic decision-making in PAH.

Purpose of the Study:

  • To outline an evidence-based treatment algorithm for pulmonary arterial hypertension (PAH).
  • To define therapeutic options for patients with NYHA class III or IV PAH.
  • To highlight considerations for specific PAH subgroups and treatment responses.

Main Methods:

  • Review of recent controlled clinical trials in PAH.
  • Analysis of treatment efficacy in idiopathic PAH and PAH associated with scleroderma or anorexigen use.
  • Evaluation of treatment algorithms based on NYHA functional class and vasoreactivity testing.

Related Experiment Videos

Main Results:

  • Treatment is primarily indicated for NYHA class III or IV patients.
  • Calcium channel blockers are reserved for a minority of acute vasoreactivity responders.
  • NYHA class III patients may receive endothelin receptor antagonists, prostanoids, or PDE5 inhibitors.
  • Continuous intravenous epoprostenol is a rescue option for NYHA class IV patients.
  • Combination therapy and interventional procedures (balloon atrial septostomy, lung transplantation) are options for refractory cases.

Conclusions:

  • An evidence-based approach is recommended for PAH treatment, tailored to patient functional class and specific disease characteristics.
  • Careful extrapolation of treatment recommendations across different PAH subgroups is necessary.
  • Advanced therapies and interventions are crucial for managing refractory PAH.